Tech Company Financing Transactions
Eradivir Funding Round
Eradivir, based in West Lafayette, secured $10 million from private investors.
Transaction Overview
Company Name
Announced On
10/7/2025
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support continued clinical development of the company's lead antiviral therapeutic for influenza, EV25, and advancement of a second molecule, EV148, for the treatment of respiratory syncytial virus (RSV).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1281 Win Hentschel Boulevard
West Lafayette, IN 47906
USA
West Lafayette, IN 47906
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Eradivir's founder, Dr. Philip S. Low, has successfully developed multiple FDA-approved targeted small molecules. These therapies all function by attaching various payloads to ligands, which bind with high specificity to diseased cells. Examples of approved molecules include a radiotherapy drug for prostate cancer and an intraoperative imaging agent for lung and ovarian cancers. Several others are currently in clinical trials (e.g., treatments for cancer, malaria, and sickle cell anemia). Eradivir was founded in March 2020 to advance a promising application of this platform in combating multiple disease states, initially focusing on influenza and other respiratory infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Low
Chief Operating Officer
Stewart Low
Chief Scientific Officer
Philip Low
Vice President
Madduri Srinivasarao
VP - R & D
Ananda Kanduluru
VP - R & D
Jeffery Nielsen
Browse more venture capital transactions:
Prev: 10/7/2025: Figment venture capital transaction
Next: 10/7/2025: Meanwhile venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs